Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC
‘Radiance is dedicated to advancing next-generation therapies for advanced cancers. RB-601™ enhances Radiance’s clinical stage pipeline and position in precision oncology. We look forward to harnessing our expertise and specialized knowledge in solid cancers to deliver meaningful outcomes to patients’ said Robert Brooks, JD, Chief Executive Officer of Radiance.
Share:
More News
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
“As the data continue to mature, we are increasingly encouraged by the preliminary findings emerging from both cohorts, particularly the overall survival trends observed in the cohort with MGMT unmethylated glioblastoma,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “These findings further reinforce our belief that targeting mitochondrial
“Based on the strong results from the BRUIN CLL-313 and CLL-314 studies, we believe Jaypirca has the potential to serve as a meaningful new option for newly diagnosed patients and those who have not yet received a BTK inhibitor,” said Jacob Van Naarden, executive vice president and president of Lilly
“The FDA’s written feedback is detailed, constructive and actionable,” said Amir Heshmatpour, Chief Executive Officer, Executive Chairman and President of NeOnc. “It provides greater clarity regarding the manufacturing, formulation and bioavailability work required to support the transition of NEO212 from the current capsule formulation to a tablet intended for late-stage